ISS Backs Radoff-JEC Group’s Push for Seer Board Overhaul
Event summary
- Radoff-JEC Group, owning 7.7% of Seer’s stock, secured ISS support for its proxy fight to replace three Seer board members.
- ISS criticized Seer’s 95% market cap loss since IPO and lack of profitability timeline before 2031.
- Proxy advisor highlighted governance concerns, including director relationships with CEO Omid Farokhzad.
- ISS noted contradictions in the board’s stance on acquisition proposals versus Farokhzad’s take-private offer.
The big picture
Seer’s struggle to achieve commercial viability post-IPO reflects broader challenges in the biotech sector, where prolonged paths to profitability often lead to activist intervention. The Radoff-JEC Group’s campaign highlights growing shareholder impatience with boards that fail to deliver tangible value despite significant market cap erosion.
What we're watching
- Governance Dynamics
- Whether ISS’s endorsement will sway enough shareholders to vote out incumbent directors at Seer’s July 28 annual meeting.
- Strategic Review
- How a potential board change could accelerate or alter Seer’s strategic review process and valuation maximization efforts.
- Market Confidence
- The pace at which investor confidence in Seer’s long-term prospects may shift following this governance challenge.